369 related articles for article (PubMed ID: 32297538)
21. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
[TBL] [Abstract][Full Text] [Related]
22. Will new agents impact survival in AML?
Rowe JM
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986
[TBL] [Abstract][Full Text] [Related]
23. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
24. Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071627
[TBL] [Abstract][Full Text] [Related]
25. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
26. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
27. Is there a standard of care for relapsed AML?
Medeiros BC
Best Pract Res Clin Haematol; 2018 Dec; 31(4):384-386. PubMed ID: 30466752
[TBL] [Abstract][Full Text] [Related]
28. Incorporating newer agents in the treatment of acute myeloid leukemia.
Raj RV; Abedin SM; Atallah E
Leuk Res; 2018 Nov; 74():113-120. PubMed ID: 30401522
[TBL] [Abstract][Full Text] [Related]
29. Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
Jaramillo S; Schlenk RF
Curr Oncol Rep; 2021 Jul; 23(9):109. PubMed ID: 34272619
[TBL] [Abstract][Full Text] [Related]
30. Novel Agents for Acute Myeloid Leukemia.
Luppi M; Fabbiano F; Visani G; Martinelli G; Venditti A
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30423907
[TBL] [Abstract][Full Text] [Related]
31. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
32. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
Wang ES
Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
[TBL] [Abstract][Full Text] [Related]
33. Progress and predictions: AML in 2018.
Rowe JM
Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
[TBL] [Abstract][Full Text] [Related]
34. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
35. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
DiNardo CD; Stein EM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
[TBL] [Abstract][Full Text] [Related]
36. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
37. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Tang K; Schuh AC; Yee KW
Curr Oncol Rep; 2021 Aug; 23(10):120. PubMed ID: 34350512
[TBL] [Abstract][Full Text] [Related]
38. New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.
Andreozzi F; Massaro F; Wittnebel S; Spilleboudt C; Lewalle P; Salaroli A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409248
[TBL] [Abstract][Full Text] [Related]
39. What's new in consolidation therapy in AML?
Schlenk RF; Jaramillo S; Müller-Tidow C
Semin Hematol; 2019 Apr; 56(2):96-101. PubMed ID: 30926097
[TBL] [Abstract][Full Text] [Related]
40. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
Wang ES
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]